{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Stoke Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"STOK"},"Address":{"label":"Address","value":"45 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States"},"Phone":{"label":"Phone","value":"+1 781 430-8200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels."},"CompanyUrl":{"label":"Company Url","value":"https://www.stoketherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Barry S. Ticho","title":"Chief Medical Officer"},{"name":"Edward M. Kaye","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}